This page provides comprehensive stock data, price information, and news for Brilliant Earth Group, Inc. (BRLT). It details financial metrics, institutional and insider trading activity, analyst ratings, and company information, noting the absence of recent congressional trading, corporate lobbying, and new patent data. The content primarily serves as a data aggregation hub for investors interested in BRLT.

Arcturus Therapeutics Holdings Inc. announced it will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 9:20 a.m. ET. The company, known for its mRNA medicines, focuses on liver and respiratory rare disease therapeutics and has developed the first approved self-amplifying mRNA COVID vaccine, KOSTAIVE®. A webcast of the presentation will be available on Arcturus's investor relations website.

Astera Labs (ALAB) stock has experienced a significant surge, climbing 48% and completing a five-day winning streak. This impressive performance highlights strong market confidence in the company, possibly driven by recent developments or positive outlooks.

Kroger has experienced a significant turnover of senior executives under its new CEO, Greg Foran, with four top leaders departing recently. These departures include key figures in human resources, retail divisions, and supply chain management, necessitating Foran to rebuild his leadership team. This period of change marks 2026 as one of the busiest years for executive turnover at the nation's largest supermarket chain.

The SPDR S&P Telecom ETF (XTL) has surged by over 120% in the last year, driven by anticipation surrounding a potential SpaceX IPO and the perceived future of space-based telecommunications. However, market observers warn that this excitement might indicate a market peak for these equities, with a significant risk of losing one-third of its value in the next 12 months. This is partly due to the ETF's equal-weighted strategy, which diversifies investments across a broad mix of traditional telecom companies and cyclical infrastructure businesses, rather than focusing solely on space exploration.

XP Inc. has updated its 2026 Annual General Meeting (AGM) board nominees, reducing the proposed directors from nine to eight after Oscar Rodriguez Herrero voluntarily withdrew his candidacy. Following his resignation, Melissa Werneck will join the Audit Committee, and José Luiz Majolo has been appointed as an independent interim director and chair of the Risks, Credit and ESG Committee until the 2027 AGM. Existing proxy cards remain valid, and votes for Mr. Rodriguez Herrero will be disregarded.

Uvalde CISD and Zurn Elkay have partnered for the "Fountains for Youth" initiative, providing a $370,000 donation of filtered bottle filling stations and conversion kits to Uvalde Consolidated Independent School District. This donation will ensure cleaner, safer drinking water for 4,000 students, faculty, and staff across five schools by reducing lead, microplastics, and other contaminants. The initiative aims to address water quality issues in communities with high lead levels and limited resources.

Exzeo Group Inc. has announced a new stock repurchase program authorizing the buyback of up to $12 million of its common shares under a Rule 10b5-1 trading plan. The authorization is effective immediately, allowing repurchases in various transaction types subject to securities law constraints, funded by the company's strong positive cash flow and debt-free balance sheet. A third-party broker will execute the discretionary program within preset parameters, with actual repurchases depending on market conditions.

Fitch Ratings upgraded YPF S.A.'s Long-Term Foreign and Local Currency Issuer Default Ratings to 'B-' from 'CCC+', aligning it with Argentina's sovereign rating which was also upgraded. The upgrade reflects the Argentine government's 51% ownership and YPF's strategic importance in the country's fuel and hydrocarbon industry. YPF's Standalone Credit Profile was also raised, although the macroeconomic environment in Argentina continues to constrain its financial flexibility.

Hims & Hers Health, Inc. (HIMS) shares are set for a weekly loss as Wall Street expresses caution about its GLP-1 growth outlook, with BofA lowering its price target due to concerns about the company's 2026 revenue guidance and intensifying competition. Despite this, former Netflix CFO and Hims board member David Wells bought 48,400 HIMS shares, signaling confidence in the company's aggressive push into weight-loss drugs, diagnostics, hormone health, and AI healthcare tools. Hims recently launched generic Semaglutide in Canada and continues to expand its obesity-care business, even as the broader GLP-1 market sees increasing competition from Eli Lilly and Novo Nordisk.